BridgeMD
New treatment option for Multiple Myeloma
Official title Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
ClinicalTrials.gov ID: NCT06057402
What this study is testing
What is Elranatamab?
Elranatamab is an investigational medicine, being studied as a potential treatment for multiple myeloma.
Also referred to as Elrexfio.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants must agree to follow the reproductive criteria as outlined in the protocol
- Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are...
You likely can't join if
- Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may...
- Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.
The study team makes the final eligibility decision.
Where it's taking place
- Irvine, California, United States
- Orange, California, United States
- Fort Collins, Colorado, United States
- Greeley, Colorado, United States
- Longmont, Colorado, United States
- Loveland, Colorado, United States
- Coral Gables, Florida, United States
- Deerfield Beach, Florida, United States
- Miami, Florida, United States
- Ann Arbor, Michigan, United States
- Detroit, Michigan, United States
- Austin, Texas, United States
- Melbourne, Victoria, Australia
- Richmond, Victoria, Australia
- Calgary, Alberta, Canada
- Edmonton, Alberta, Canada
- Montreal, Quebec, Canada
- Beijing, Beijing Municipality, China
- Guangzhou, Guangdong, China
- Jinan, Shandong, China
+ 6 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Irvine, California, United States; Orange, California, United States; Fort Collins, Colorado, United States; Greeley, Colorado, United States; Longmont, Colorado, United States; Loveland, Colorado, United States and 20 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.